Chinese Prostate Cancer Genome and Epigenome Atlas

Introduction

Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA) is the largest and most comprehensive cancer genomics study conducted in China. Our genome and epigenome roadmap of prostate cancer for Chinese men is consisted of over 1200 genomic datasets from more than 200 pairs of matched normal and primary prostate cancers, providing an invaluable resources and opportunity to complement and compare to previous cancer genomics studies represented by TCGA.


Summary


Alalysis Workflow Sequencing Info Somatic Alterations Validation
DNA-seq WGS Somatic coding mutations (MAF File)
Somatic CNV (Control-FreecGistic)
Somatic SV (Meerkat Result)
FOXA1 Mutation Validation
SV Validation
RNA-seq Lnc-RNA
Samll RNA
Fusion (SOAPfuse ResultGeneral Result) Fusion Validation
DNA-methylation WGBS DMR (DMR Result) -

Public Data


Study Mutations Fusions CNAs
cpcg_2017+
su2c_2015+++
mskcc_2017+++
wcm_2016++
broad_2013+++
broad_2012++
eururol_2017+++
fhcrc_nm_2016++
mskcc_2010++
mskcc_dfci_ng_2018+++
tcga_pub+++
mskcc_2014+
mskcc_cheny_2014+
mich_2012+++


Copyright © Department of Urology, Changhai Hospital & Center for Translational Medicine. All rights reserved.